CalciMedica (NASDAQ:CALC) Releases Earnings Results, Beats Estimates By $0.14 EPS

CalciMedica (NASDAQ:CALC) announced its quarterly earnings data on Thursday. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.14, Zacks reports.

CalciMedica Price Performance

Shares of NASDAQ CALC traded up $0.14 during trading hours on Thursday, reaching $2.13. The stock had a trading volume of 16,085 shares, compared to its average volume of 43,939. CalciMedica has a twelve month low of $1.83 and a twelve month high of $6.27. The company has a market cap of $28.70 million, a price-to-earnings ratio of -1.94 and a beta of 1.20. The business’s fifty day moving average is $2.43 and its two-hundred day moving average is $3.19.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of CalciMedica in a report on Tuesday, March 4th.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.